| |
Screening
|
Evaluation
|
|---|
| | |
Baseline
|
6 months
|
12 months
|
18 months
|
24 months
|
|
Eligibility criteria
|
x
| | | | | |
|
Informed consent
|
x
| | | | | |
|
Health care use
| | |
x
|
X
|
x
|
x
|
|
MCSI
| |
x
|
x
|
x
|
x
|
x
|
|
CGI
| |
x
|
x
|
x
|
x
|
x
|
|
MINI
| |
x
|
x
|
x
|
x
|
x
|
|
MARS
| |
x
|
x
|
x
|
x
|
x
|
|
SF-36
| |
x
|
x
|
x
|
x
|
x
|
|
S-QoL 18
| |
x
|
x
|
x
|
x
|
x
|
|
EuroQoL 5D
| |
x
|
x
|
x
|
x
|
x
|
|
RAS
| |
x
|
x
|
x
|
x
|
x
|
|
MCAS
|
x
|
x
|
x
|
x
|
x
|
x
|
|
Ad hoc questionnaires
| |
x
|
x
|
x
|
x
|
x
|
|
Cost analysis
| | |
x
|
x
|
x
|
x
|
-
CGI, clinical global impression; Health care use, number of admissions to hospital, total days in hospital and number of emergency department visits; MARS, medication adherence rating scale (MARS); MCAS, Multnomah community integration scale MINI, mini international neuropsychiatric interview, sections K and L; MCSI, modified Colorado symptom index; RAS, recovery assessment scale; SF-36, medical outcomes study 36-item short form health survey; S-QoL 18, schizophrenia quality of life questionnaire.
